This document discusses copay subsidy programs that target certain drugs and how health plans should respond. It notes that subsidies often target non-formulary drugs, drugs that recently lost patent protection, or high-cost specialty medications. These programs work by providing physical or digital cards to patients to lower their copayment at the point of sale. The document recommends ways for health plans to respond, such as increasing costs for non-formulary drugs, making generics cheaper, implementing step therapy, and partnering with manufacturers on specialty drugs to lower costs while supporting adherence.